Glutamate-based Therapies for Psychiatric Disorders

1. Front Matter

   Pages i-xiv

   PDF

2. N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression

   • Phil Skolnick, Piotr Popik, Ramon Trullas

   Pages 1-20

3. Ionic Glutamate Modulators in Depression (Zinc, Magnesium)

   • Bernadeta Szewczyk, Ewa Poleszak, Andrzej Pilc, Gabriel Nowak

   Pages 21-38

4. Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy

   • Eric S. Nisenbaum, Jeffrey M. Witkin

   Pages 39-56

5. Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors

   • Jeffrey M. Witkin

   Pages 57-74

6. Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders

   • Gary Lynch, Julie C. Lauterborn, Christine M. Gall

   Pages 75-100

7. Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia

   • Douglas J. Sheffler, P. Jeffrey Conn

   Pages 101-116

8. mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia

   • Hisashi Ohta, Hiroshi Kawamoto, Gentaroh Suzuki

   Pages 117-131

9. Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence

   • Svetlana Semenova, Athina Markou

   Pages 133-156

10. Metabotropic Approaches to Anxiety

    • Joanna M. Wieronska, Gabriel Nowak, Andrzej Pilc

    Pages 157-173

11. Back Matter

    Pages 175-178

    PDF

Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.

• Nervous System
• antidepressant effect
• brain
• brain injury
• depression
• drug
• drug abuse
• psychiatric disorder
• receptor
• research
• schizophrenia
• therapy
• trauma
• traumatic brain injury
• zinc
• psychopharmacology

From the reviews:

“This book summarizes the translational research in the development of glutamate-based approaches to treat psychiatric disorders. Written and edited by an international group of researchers, it is an important addition to the psychiatric literature. … The intended audience includes psychiatric researchers and psychiatrists. Neuroscientists interested in the treatment of patients with psychiatric disorders also would benefit from reading this book. … The index is quite helpful. … presents a unique and novel approach that is desperately needed in the treatment of these difficult disorders.” (Michael Joel Schrift, Doody’s Review Service, February, 2011)

• Div Pharmacotherapies & Medical Conseque, National Institute on Drug Abuse, Rockville, USA

  Phil Skolnick

Policies and ethics